Larimar CDO granted 153,822 options, 25,637 shares

Larimar Therapeutics reported an insider equity award for Chief Development Officer Shankar Gopi.

Rhea-AI Filing Summary

Larimar Therapeutics reported an insider equity award for Chief Development Officer Shankar Gopi. On January 26, 2026, he received 153,822 stock options with a $3.60 exercise price and vesting over four years, starting 25% on January 26, 2027, then monthly thereafter.

He also acquired 25,637 shares of common stock for $0.00 per share, represented by restricted stock units, bringing his directly held common stock to 76,443 shares. All transactions were classified as awards and reported as directly owned.

Insider Trade Summary

Grant/Award: 179,459 shares

Grant/Award 2 txns

Insider Shankar Gopi

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	153,822	$0.00	$0.00
Grant/Award	Common Stock	25,637	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 153,822 contracts (Direct); Common Stock — 76,443 shares (Direct)

Footnotes (2)

1. F1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
2. F2. The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Larimar Therapeutics (LRMR) report for Shankar Gopi?

Larimar Therapeutics reported equity awards to Chief Development Officer Shankar Gopi. He received 153,822 stock options and 25,637 shares of common stock as part of an award, with no cash price paid for either grant.

How many Larimar Therapeutics (LRMR) stock options were granted to Shankar Gopi?

Shankar Gopi was granted 153,822 stock options. These options have a $3.60 exercise price and are scheduled to vest over four years, subject to his continued service with Larimar Therapeutics through each applicable vesting date.

What is the vesting schedule for Shankar Gopi’s Larimar Therapeutics stock options?

The stock options vest 25% on January 26, 2027. The remaining 75% vests in equal monthly installments over the next 36 months, contingent on Shankar Gopi’s continued service with Larimar Therapeutics during the vesting period.

How many Larimar Therapeutics (LRMR) common shares does Shankar Gopi own after this Form 4?

After the reported transactions, Shankar Gopi beneficially owns 76,443 shares of Larimar Therapeutics common stock. This total includes 25,637 shares acquired for $0.00 per share represented by restricted stock units that settle into common shares.

Were the Larimar Therapeutics (LRMR) equity awards to Shankar Gopi purchases or grants?

The equity awards to Shankar Gopi were grants, not open-market purchases. Both the 153,822 stock options and 25,637 common shares were reported with a transaction code “A” for awards and a price of $0.00 per share.

What role does Shankar Gopi hold at Larimar Therapeutics (LRMR)?

Shankar Gopi serves as Chief Development Officer at Larimar Therapeutics. The Form 4 identifies him as an officer, with the reported stock option and stock grants reflecting compensation tied to his executive position at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 05:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shankar Gopi

(Last) (First) (Middle)

C/O LARIMAR THERAPEUTICS, INC.

THREE BALA PLAZA EAST, SUITE 506

(Street)

BALA CYNWYD PA 19004

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Larimar Therapeutics, Inc. [ LRMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		25,637(1)	A	$0.00	76,443	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.6	01/26/2026		A		153,822		(2)	01/26/2036	Common Stock	153,822	$0.00	153,822	D

Explanation of Responses:

1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

2. The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

	/s/ Jennifer Johansson, Attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.